MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.8 USD | -2.01% |
|
-10.98% | +19.41% |
| Jun. 28 | Moderna: positive CHMP opinion on RSV | CF |
| Jun. 28 | Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation | MT |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.41% | 45.51B | |
| +38.65% | 39.36B | |
| -8.62% | 38.52B | |
| +26.95% | 30.74B | |
| -13.50% | 26.03B | |
| +10.74% | 25.92B | |
| +44.87% | 14.13B | |
| +34.36% | 12.73B | |
| -7.14% | 11.29B | |
| -12.61% | 10.64B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna Shares Fall as RSV Shot Efficacy Lags Behind Rivals' Vaccines, CDC Data Shows
